HBEGF and in situ carcinoma: HB-EGF is elevated in the cerebrospinal fluid (CSF) of CIS patients compared with RRMS patients, suggesting that CSF HB-EGF could be a potential biomarker for diagnosing CIS and discriminating between non-CIS vs. CIS patients [75].